Stopping a GLP-1: What Research Shows About Weight Regain and What to Track

Starting a GLP-1 medicine gets most of the attention. Stopping one gets far less, even though many people pause, taper or stop at some point. Cost, side effects, supply problems, a pregnancy plan or simply reaching a goal can all lead to that conversation with a provider.

So what actually happens to weight after a GLP-1 is stopped? Three large trials have looked at this directly. This post walks through what they found in plain language, what the results do and do not tell you, and how a GLP-1 tracker app can help you and your provider see what is really going on if you ever make that change.

This is general information, not advice. Whether to continue, pause or stop is always a decision for you and your licensed healthcare provider.

What the research looked at

The question is simple: if someone loses weight on a GLP-1 and then stops, does the weight stay off? To answer it, researchers used a design called a withdrawal study. Everyone starts on the medicine. Later, some participants keep going and others are switched to a placebo, usually without knowing which group they are in. Then both groups are followed for months.

STEP 1 extension (semaglutide)

The STEP 1 trial extension followed a subset of 327 adults for one year after semaglutide and the study's lifestyle program both ended at week 68. During treatment, the semaglutide group lost an average of 17.3% of their body weight. One year after stopping, they had regained about two thirds of that loss on average, leaving a net loss of 5.6% from where they began.

The authors also reported that improvements in cardiometabolic measures, such as blood pressure and blood sugar markers, drifted back toward baseline for most variables. Their conclusion was that obesity behaves like a chronic condition and that ongoing treatment appeared to be needed to keep the improvements.

STEP 4 (semaglutide)

STEP 4 took a slightly different approach. All 803 randomized participants had been on semaglutide for 20 weeks and had lost about 10.6% of their weight on average. They were then split into two groups. Those who continued lost a further 7.9% over the next 48 weeks. Those switched to placebo regained 6.9% over the same period. Both groups kept a lifestyle program throughout.

SURMOUNT-4 (tirzepatide)

SURMOUNT-4 ran the same kind of test with tirzepatide. After a 36-week lead-in, participants had lost 20.9% of their weight on average. Over the next 52 weeks, people who continued lost a further 5.5%, while those switched to placebo regained 14.0%. Among those who continued, 89.5% kept at least 80% of their earlier loss, compared with 16.6% in the placebo group.

What these results do and do not mean

The pattern across all three trials is consistent. On average, weight tended to come back after stopping, and it tended to hold or keep falling for people who continued. That said, a few points are worth keeping in mind before drawing personal conclusions.

• These are averages. Some people in the placebo groups regained very little, and others regained more than average. The trials describe groups, not individuals.
• Stopping was abrupt in the trials. Participants went from the medicine straight to placebo. The studies were not designed to compare different ways of stepping down, so they do not settle how a gradual change might go.
• Lifestyle support differed. In the STEP 1 extension, the lifestyle program ended along with the medicine. In STEP 4 and SURMOUNT-4, it continued. That makes direct comparisons between the trials harder.
• Most trial participants did not have diabetes. Results may look different for other groups.

None of this means anyone has to stay on a GLP-1 forever, and none of it means stopping is wrong. It means the change deserves a plan, and a plan works better when you have good records.

Why tracking matters more around a change

When you stay on the same routine for months, small day to day changes blur together. Around a pause or a stop, they suddenly matter. A provider will usually want to know what changed, when it changed and what happened after. Memory is not reliable for that, especially across several weeks.

A simple record lets you answer questions like these with real dates instead of guesses:

• When was the last dose logged, and was it on time?
• Did the provider set out a step-down plan, and were the steps followed as written?
• How did weight move in the four, eight and twelve weeks after the change?
• Did appetite, nausea or other check-ins shift after the change?

What to record before the change

Before anything changes, it helps to have a clean baseline. That means a few weeks of consistent dose history, a weight trend logged at a similar time of day, and notes on how you have been feeling. If your provider set out a stepped plan, write the steps exactly as they gave them. A titration schedule log works in both directions, for stepping up and for stepping down.

What to record after the change

After the change, keep logging weight on the same schedule you used before. Many people stop tracking at exactly the moment the data becomes most useful. A steady weight tracking habit shows whether the trend is flat, rising slowly or rising quickly. That is the kind of detail a provider can act on.

It is also worth noting any side effect check-ins, sleep changes or big shifts in routine, such as travel or a new job. These help explain a trend instead of leaving everyone to guess.

Bringing the record to your provider

A short summary beats a long story. Before an appointment, pull together:

1. The date of your last dose and the date of any plan change.
2. Your weight trend over the last two to three months.
3. Any side effect or appetite notes, with dates.
4. Questions you want answered, written down in advance.

Your provider may compare your trend with what the research shows on average, or they may focus entirely on your own history. Either way, a clear record keeps the conversation grounded in facts.

Keeping it simple

You do not need a complicated system. A notebook or spreadsheet can work if you keep it up. A dedicated GLP-1 tracker app can make it easier, because doses, weight and check-ins sit on one timeline. Peppy is one option. It keeps your dose log, weight chart and check-ins together on your iPhone, with no account needed, and you can read more on the GLP-1 tracker page. If you are on a specific medicine, the semaglutide tracker and tirzepatide tracker pages explain how those records fit together.

The short version

Research on semaglutide and tirzepatide shows that, on average, weight tends to return after these medicines are stopped, while people who continue tend to maintain their loss. Averages are not destinies, and the right path is a decision for you and your provider. What you can control is the quality of your record. Keep logging doses, weight and how you feel before and after any change, and bring that record to every appointment.